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Chemotherapy-induced neuropathic pain is a dose-limiting side effect of many cancer therapies due to their
propensity to accumulate in peripheral nerves, which is facilitated by the permeability of the blood-nerve
barrier. Preclinically, the chemotherapy agent vincristine (VCR) activates endothelial cells in the murine per-
ipheral nervous system and in doing so allows the infiltration of monocytes into nerve tissue where they or-
chestrate the development of VCR-induced nociceptive hypersensitivity. In this study we demonstrate that VCR
also activates endothelial cells in the murine central nervous system, increases paracellular permeability and
decreases trans endothelial resistance. In in vivo imaging studies in mice, VCR administration results in traf-
ficking of inflammatory monocytes through the endothelium. Indeed, VCR treatment affects the integrity of the
blood-spinal cord-barrier as indicated by Evans Blue extravasation, disrupts tight junction coupling and is ac-
companied by the presence of monocytes in the spinal cord. Such inflammatory monocytes (Iba-1+ CCR2+
Ly6C+ TMEM119- cells) that infiltrate the spinal cord also express the pro-nociceptive cysteine protease
Cathepsin S. Systemic treatment with a CNS-penetrant, but not a peripherally-restricted, inhibitor of Cathepsin S
prevents the development of VCR-induced hypersensitivity, suggesting that infiltrating monocytes play a func-
tional role in sensitising spinal cord nociceptive neurons. Our findings guide us towards a better understanding
of central mechanisms of pain associated with VCR treatment and thus pave the way for the development of
innovative antinociceptive strategies.
1. Introduction
Neuropathic pain results from central nervous system (CNS) and
peripheral nervous system (PNS) lesions that are accompanied by sig-
nificant immune responses, such as those elicited by monocytes/mac-
rophages and microglia (CNS-resident macrophages). These immune
cells produce inflammatory mediators that contribute to neuropathic
pain by activating nociceptive neurons (Costigan et al., 2009). The
mechanisms that govern the involvement of immune cells however,
differs between the CNS and PNS.
Injury in the CNS such as that caused by traumatic spinal cord le-
sions can result in disruption of the integrity of the blood–brain barrier
and the consequential infiltration of inflammatory monocytes, which
express the chemokine receptor CCR2. Such infiltration, along with
microglial responses, exacerbates neuronal damage and pain. For in-
stance, in CNS conditions such as spinal cord injury, CCR2+ monocytes
infiltrate the dorsal column and facilitate neuronal damage (Evans
et al., 2014). Here they are recruited by the chemokine CCL2, which is
expressed by perivascular macrophages and microglia, and contribute
to inflammation (Varvel et al., 2016).
In the instance of PNS injury however, the role of monocytes and
macrophages has been shown to remain peripheral. Resident macro-
phages in the dorsal root ganglia (DRG) produce soluble factors, which
induce the recruitment of neutrophils and monocytes (Santa-Cecília
et al., 2019). In addition, as a consequence of endothelial cell activa-
tion, monocytes are able to infiltrate into peripheral nerves following
PNS injury, where they orchestrate the development of mechanical
hypersensitivity (Old et al., 2014). This however, is not mirrored
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centrally where it is the microglial that respond to injury-induced in-
creases in nociceptive neuron activity. For instance, microglia release
the cysteine protease Cathepsin S (CatS) that solubilises the chemokine
domain of neuronal fractalkine (FKN), which in turn activates the
CX3CR1 chemokine receptor in microglia (Clark et al., 2007; Clark
et al., 2009). FKN activation of CX3CR1 results in the release of pro-
nociceptive cytokines, such as IL-1β (Clark et al., 2015, Innes et al.,
2019), that induce neuronal sensitisation and facilitates pain signalling
as well as other pathological conditions.
Peripheral nerve injury manifests during and after treatment with a
variety of chemotherapeutic agents, which have a broad range of ac-
tions with both shared and drug-specific underlying mechanisms. The
blood-nerve barrier is relatively permeable as a result of low activity of
the P-glycoprotein transporter (Balayssac et al., 2005). Chemother-
apuetic agents consequently accumulate in peripheral nerves and cause
neurotoxicity associated with monocyte infiltration/resident macro-
phage activation in peripheral nerves and the DRG, as well as sig-
nificant nociceptive hypersensitivity (Old et al., 2014; Zhang et al.,
2016; Shen et al., 2017; Montague et al., 2018). For example, in the
case of hyperalgesia induced by oxaliplatin, a higher concentration of
the drug is found in the DRG compared to the spinal cord and is critical
for activation of resident macrophages (Shen et al., 2017). Another
chemotherapeutic agent, which results in painful peripheral neuro-
pathy is the vinca alkaloid vincristine (VCR). VCR treatment is asso-
ciated with significant nociception, which is orchestrated by monocyte
infiltration into peripheral nerves. Specifically, VCR treatment induces
the expression of the adhesion molecules ICAM-1 and VCAM-1 in en-
dothelial cells and consequently promotes the infiltration of patrolling
monocytes (CX3CR1high monocytes) into the sciatic nerve, later fol-
lowed by inflammatory monocytes (CCR2high/CX3CR1mid) as treatment
progresses. Both patrolling and inflammatory monocytes facilitate
noxious signalling through the release of cytokines and reactive oxygen
species (ROS), which sensitise sensory neurons (Old et al., 2014;
Montague et al., 2018). Indeed, pharmacological impairment of
monocyte trafficking in peripheral nerves both prevents and reverses
VCR-induced mechanical hypersensitivity (Montague and Malcangio,
2017). Importantly, whilst monocytes/macrophages play a mechanistic
role in pain associated with VCR treatment, changes in microglial
number and morphology centrally and are not apparent when clini-
cally-relevant doses of VCR are administered, as is the case with other
chemotherapeutic agents (Zheng et al., 2011; Old et al., 2014).
The clinical preparation of VCR – vincristine sulphate, is a large
molecule (933 g/mol) which, despite passing through the peripheral
blood-nerve barrier, does not accumulate centrally as it does not cross
through the blood–brain barrier (BBB) or blood-spinal cord barrier
(BSCB) where P-glycoprotein transporter efficiently limits drug dis-
tribution (Balayssac et al., 2005; Wang et al., 2010). The endothelial
cells that form both the BBB and BSCB are tight junction-coupled.
Proteins that constitute tight junctions include claudins, which form
part of the extracellular component, and zona occludens proteins,
which are one of the building blocks of the cytoplasmic component of
the junction (Findley and Koval, 2009). The presence of tight junctions
effectively restricts paracellular diffusion (Abbott et al., 2010).
In this study we explored whether VCR activates endothelial cells in
the CNS and alters the integrity of the BSCB. We expand our knowledge
regarding the role of monocyte signalling in VCR-induced nociception
and begin to uncover a role for monocytes that infiltrate into the spinal
cord as an indirect result of VCR treatment. Specifically, we uncover
what we believe to be a previously unidentified alteration in vascular
permeability of the BSCB that is mediated by VCR. We also investigate
the effect of treatment with inhibitors of CatS on VCR-induced noci-
ception. We use both peripherally-restricted and centrally-penetrant
CatS inhibitors in order to assess the importance of central versus per-
ipheral monocyte-derived CatS-regulated mechanisms. Our findings
guide us towards a better understanding of central mechanisms of pain
associated with VCR treatment and thus pave the way for the
development of innovative therapeutic strategies.
2. Materials & methods
2.1. Animals
Experiments were performed in accordance with the United
Kingdom Animals (Scientific Procedures) Act 1986 and local animal
care and use guidelines. All mice were housed under a 12 h light/dark
cycle, with food and water available ad libitum. For behavioural ex-
periments both male and female cx3cr1-gfp (heterozygous and thus
normal cx3cr1 function) were used (25–30 g, 16 weeks of age). For
Evans Blue experiments C57Bl/6 male and female mice (25–30 g,
12–17 weeks of age) were used. For intravital experiments and im-
munohistochemistry CCR2-RFP (red fluorescent protein) mice were
used for which an original breeding stock was purchased from Jackson
Laboratory having been generated from a C57BL/6 background. CCR2
disruption/RFP expression was confirmed by PCR using published pri-
mers (Montague et al., 2018).
2.2. Behavioural testing
Static mechanical withdrawal thresholds were assessed as pre-
viously described (Pitcher et al., 2016). Briefly, unrestrained mice were
acclimatised in custom-made chambers for 1 h prior to testing. Cali-
brated von Frey filaments (0.008–1.04 g) were gently applied to the
hind paw (plantar surface) until they started to bend and were held in
place either for 3 s or until the paw was withdrawn. The 50% paw
withdrawal threshold (grams) was calculated using the ‘up-down’
method (starting with the 0.7 g filament). Three baseline measurements
were taken prior to experimentation, the mean of which is presented.
Data presented are means of the left and right hind paw thresholds
(which show no difference from each other). All behavioural tests were
conducted by an experimenter blinded to the treatment regime.
2.3. Drug administration
Vincristine sulphate (933 g/mol, Sigma-Aldrich) was dissolved in sterile
saline 0.5mg/kg/day and injected intraperitoneally (i.p.) using a 25-g
needle either as a one-off injection (for 24 h experiments) or one cycle (days
0–4 inclusive). RO5461111 (Rupanagudi et al., 2015) and MIV-247 ((S)-N-
(1-(2-amino-2-oxoacetyl)cyclobutyl)-2-(2,2-difluoropropanamido)-3-(1-
fluorocyclopentyl) propenamide) (Hewitt et al., 2016) were a gift from
Medivir and were both administered orally at 200 µmol/kg twice a day for
each day of VCR treatment. MIV-247 was supplied pre-formulated in 20%
2-Hydroxypropyl-beta-cyclodextrin (HP-β-CD) that was used as vehicle
control and administered at 5ml/kg (Hewitt et al., 2016). RO54461111 was
dissolved in 0.5% methylcellulose in distilled water (that was used as ve-
hicle control) and also administered at 5ml/kg.
2.4. Immunohistochemistry
Mice, under pentobarbital anaesthesia were transcardially perfused
with saline and 4% paraformaldehyde (PFA) as described previously
(Montague et al., 2018). The lumbar enlargement was excised and post-
fixed for 4 h before being dehydrated in 30% sucrose and subsequently
embedded in optimum cutting temperature-embedding medium (VWR)
and snap frozen on dry ice. Fifteen μm sections were obtained and
mounted on Superfrost Plus sides (VWR). Sections were permeabilised
for 15min at room temperature in 0.1% PBS-Triton X-100 (Sigma-Al-
drich) then blocked in 0.1% PBS-Triton X-100+ 3% BSA (Sigma-Al-
drich) for 1 h at room temperature before being incubated in primary
antibody at 4 °C for 16 h. Slides were washed three times in 0.1% PBS-
Triton X-100, before being incubated with the appropriate fluorescently
tagged secondary antibody for 1.5 h at room temperature. Slides were
washed three times again before being incubated for 5min in DAPI
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diluted in PBS at 1:2000 before being washed again and then mounted
using FluorSave™ (Merck, UK). Slides were visualised under a Zeiss
LSM710 confocal microscope (Zeiss). Five sections per mouse were
randomly selected and analysed blind as described previously (Old
et al., 2014).
2.5. Antibodies
For monocyte/macrophages expression anti-Ly6C (1:200 Abcam)
was used and followed by anti-rat Alexa 488 (1:1000, Invitrogen). To
visualise microglia/macrophages, resident microglia, claudin-5 and ZO-
1, anti-Iba1 (1:1000 WAKO), anti-TMEM119 (1:500, Abcam), anti-
claudin-5 (1:500, Abcam) and anti-zo-1 (1:500, ThermoFisher scien-
tific) were used, respectively. All were followed by anti-rabbit Alexa
Fig. 1. VCR induces activation of CNS en-
dothelial cells. Bend3 cells were incubated
with Vincristine (100 nM) or saline control
for 24 h. (A) Representative FACS profile
showing the intensity of fluorescence for
ICAM expression. (B) Quantification of
ICAM expression (n= 3 independent ex-
periments). (C) Representative FACS profile
showing the intensity of fluorescence for
VCAM expression. (D) Quantification of
VCAM (n=3 independent experiments).
(E) Representative FACS profile showing the
intensity of fluorescence for P-glycoprotein
expression. (F) Quantification of PGP-1 ex-
pression (n=3 independent experiments).
(G) Trans-endothelial resistance (TEER)
(n=3 independent experiments). (H)
Paracellular permeability expressed as per-
meability coefficient of bEND3 cells treated
with VCR. Values are mean ± SEM.
Statistical analysis was performed by using
Student’s t test *p < 0.05 compared to
saline treated cells.
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488 (1:1000, Invitrogen). To visualise CatS, anti-CatS (1:100, Santa
Cruz) was used followed by anti-mouse Alexa 488 (1:1000, Invitrogen).
For FACS analysis reported below the following antibodies were used:
occludin monoclonal antibody OC-3F10 (1:100, Invitrogen) P-glyco-
protein monoclonal antibody C213 (1:10, Thermo Fisher Scientific).
ICAM-1/VCAM-1, anti-mouse CD54 (1:200, e-BioLegend) and anti-
mouse CD106 (1:200, e-BioLegend). Secondary coupled antibody used
for occludin and p-Glycoprotein was an anti-mouse Alexa 488 (1:200,
Life Technology).
2.6. Western blot analysis
Sciatic nerves and lumbar spinal cords (dorsal) were fresh-dissected,
snap-frozen and stored at −80 °C until use. Tissue was homogenised in
ice-cold RIPA buffer (20mM tris(hydroxymethyl)aminomethane;
10mM NaF; 150mM NaCl; 1% nonyl-phenoxylpolyethoxylethanol;
1 mM phenylmethanesulfonyl fluoride; 1mM Na3VO4 (all Sigma-
Aldrich); and 10mg/ml proteinase inhibitor (Roche)) before being in-
cubated at 4 °C with agitation for 2 h. Samples were then centrifuged at
4 °C and 13,000 rpm for 20min and the supernatant obtained was used
for Western blot. Protein concentration was determined using the bi-
cinchoninic acid (BCA) protein assay (Pierce). Twenty micrograms of
protein per sample was separated on a 15% SDS-PAGE gel (or 8% gel
for ZO-1) and transferred onto a nitrocellulose membrane in accordance
with manufacturer’s instructions (Bio-Rad, UK). Blots were blocked for
1 h at room temperature in 0.1% TBS-Tween-20 (TBST)+ 5% skimmed
milk before being incubated in the required primary antibody (CatS at
1:500, Santa Cruz; Claudin-5 at 1:1000, Abcam; ZO-1 at 1:1000,
ThermoFisher Scientific) at 4 °C overnight along with a loading control
(β-actin (mouse or rabbit) 1:1000, Abcam). After washing in 0.1% TBST
five times, blots were incubated for 1 h at room temperature with the
appropriate HRP-conjugated secondary antibody (1:2000, DAKO). Blots
were washed before being developed with Luminata Forte Western HRP
Substrate (Millipore). Bands were visualised using BioSpectrum©
Imaging and quantified using Quantity One (Bio-Rad, UK).
2.7. In vivo imaging
CCR2-RFP mice were anaesthetised with an initial dose of urethane
(12.5% w/v, 0.3ml IP). Further doses were administered approximately
every 15min to achieve surgical anaesthetic depth. Throughout the
surgery and imaging period mice were maintained close to 37 °C, using
a homeothermic heating mat and rectal probe. For increased stability
and ease of breathing a tracheal catheter was installed but mice re-
mained freely breathing. An incision was made in the skin above the
lumbar enlargement and the spinal column was stabilised on a custom-
made stage using spinal camps (Precision Systems and
Instrumentation). Vertebrae over L3 and L4 spinal segment were re-
moved in a laminectomy and the exposed spinal cord was cleaned and
moistened with saline and covered with silicone elastomer (World
Precision Instruments, Ltd). To visualise blood vessels, mice received an
intravenous injection of 50 µl dextran fluorescein (12.5mg/ml; mole-
cular weight: 70,000), prior to imaging. Mice were placed under an
Eclipse Ni-E FN upright confocal/multiphoton microscope (Nikon)
where the ambient temperature was maintained at 32 °C and core body
temperature continued near 37 °C. Images were acquired using a 20×
extra-long working distance dry objective. Dextran signal was obtained
using a 488 nm Argon ion laser whilst RFP fluorescence was obtained
Fig. 2. Increased monocyte adhesion to
and infiltration into the spinal cord 24 h
after one dose of VCR. (A-B)
Representative images from a time
series of spinal cords taken from saline
(A) and VCR-treated (B) mice. Blood
vessels are labelled with dextran fluor-
escein (green) and monocytes are
tagged with CCR2-RFP (red). Scale
bar= 100 μm. (C) Quantification of the
number of CCR2-RFP+ profiles ob-
served outside of the vessel. One dose of
VCR significantly increases RFP+ pro-
files found in spinal cord tissue
(mean ± SEM, n=5 mice per group).
*p < 0.05, Student’s paired t-test. (D)
Quantification of the number of CCR2-
RFP+ profiles observed at the en-
dothelium. One dose of VCR sig-
nificantly increases RFP+ profiles
found in spinal cord tissue
(mean ± SEM, n=5 mice per group).
*p < 0.05, Student’s paired t-test. (For
interpretation of the references to
colour in this figure legend, the reader
is referred to the web version of this
article.)
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using 561 nm diode laser. To detect the presence of blood vessels a
single image of the Dextran and RFP signal was taken before and after
time-lapse recording while RFP+ monocyte movement and adhesion
was recorded for between 20 and 60min using only RFP acquisition.
2.8. bEND.3 cell culture
The bEND3 (Immortalized Murine Brain Microvascular Endothelial
Cell) cell line was obtained from ECACC. They originate from mouse
SV129 brain endothelioma.
The bEND3 cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) 4.5 g/L D-Glucose+GlutaMAX medium (Gibco,
Thermo Fisher Scientific, UK) with 10% of foetal bovine serum (FBS-
Sigma), 1:100 Non-essential Amino Acid Solution (NEAA) and 1:1000
Gentamicin (Gibco_Thermo Fisher Scientific-UK)
2.9. FACS analysis
bEND3 cells (1× 106) were fixed with 100 μl of 2% paraf-
ormaldehyde (PFA) (Sigma-Aldrich, UK) for 10min at RT. The cells
were incubated in 100 µl of primary antibody against the antigens:
occludin, P-glycoprotein, ICAM and VCAM in FACS buffer (1% Bovine
Serum Albumin in Phosphate buffered saline (PBS) with Ca2+ and
Mg2+) in the dark for 30min.
When the first antibody was not coupled, cells were further in-
cubated with a secondary antibody (100 µl) for 30min at RT. Sample
were washed in FACS buffer, suspended in 200 µl PBS, and analyzed at
the FACS machine (BDFortessa, BD, UK) using a blue laser for occludin
and P-glycoprotein Alexa fluor 488 (B530/30), violet for Pacific blues
VCAM (V450/50) or Red laser for APC labelled antibody ICAM (R670/
14).
2.10. Paracellular permeability
bEND3 cells were grown on Transwell polycarbonate filters (pore
size, 0.4 μm; Sigma-Aldrich) coated with calf skin collagen type I
(Sigma-Aldrich) and paracellular permeability of 70-kDa FITC-dextran
was assessed after stimulation as previously described (Dehouck et al.,
1992); The permeability coefficient and clearance were calculated from
the initial concentration of tracer in the luminal chamber and final
concentration in the abluminal chamber: Clearance (FITC)= [C]l * Vl/
[C]u where [C]u is the initial luminal tracer concentration, [C]l is the
abluminal tracer concentration and Vl is the volume of the abluminal
chamber. Concentration values of the lower chamber were calculated
by plotting a standard curve of known amounts of FITC-dextran. An
increment of cleared volumes was plotted against time of measurement
(60min). The total resistance coefficient opposed to the passage of the
dye is the sum of the resistance offered by the monolayer and the one
offered by the filter itself (PStot). The slope of the clearance curve with
a control membrane was denoted by PSmembrane. The real PS value for
the bEND3 monolayer (PStrans) was calculated from 1/PStot. The
PStrans values were divided by the surface area of the Transwell inserts
to generate the permeability coefficient (Ptrans, in cm/min). Each ex-
perimental repeat was performed in duplicate and over at least 3–5
independent experiments.
Transendothelial resistance (TEER) across the monolayer was de-
termined by using an Endohmeter (World Precision Instruments).
Resistance from coated cell-free inserts was always subtracted from the
resistance obtained in the presence of endothelial cells.
2.11. Evans blue injections and extraction from tissue
Evans Blue powder was purchased from Sigma, UK and dissolved in
sterile 0.9% saline at a concentration of 50mg/ml. The solution was
then filtered and administered intravenously into the lateral tail vein of
C57Bl6 mice at 50mg/kg. Mice were placed back in their cages and
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Fig. 3. One cycle of VCR treatment
significantly increases vascular perme-
ability in brain and spinal cord. (A)
Observation of paws prior to tissue
harvesting showed no obvious differ-
ence in Evans Blue (EB) accumulation
between saline-treated and VCR-treated
mice. (B) Quantification of EB (ex-
pressed as ng/mg of tissue) in liver
tissue from saline- and VCR-treated
mice (mean ± SEM, n= 7–8 mice per
group). (C,D) Quantification of EB in
brain (C) and spinal cord (D) from
saline- and VCR-treated mice
(mean ± SEM, n= 7–8 mice per
group). **p < 0.01, ***p < 0.005,
one-way ANOVA, post-hoc Tukey test.
(For interpretation of the references to
colour in this figure legend, the reader
is referred to the web version of this
article.)
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observed regularly before tissue was fresh-dissected at 24 h after in-
jection. Tissue was cut in to small pieces and weighed (approx. 300mg)
and incubated in 500 μl saline for 2 h. Solutions were then centrifuged
at 10,000 rpm for 10min. The supernatants were then treated with 1:2
trichloroacetic acid (TCA) before being centrifuged at 10,000 rpm for
20min (Wang and Lai, 2014). The final supernatant was then used to
measure absorbance at 620 nm and concentration determined using
standardized EB solutions (0.025–1000 μg/ml). EB was then expressed
as ng/mg of tissue.
3. Results
3.1. Vincristine upregulates adhesion molecules in CNS endothelial cells in
vitro
In order to elucidate whether VCR could alter permeability of the
BSCB, we began with an in vitromodel of endothelial cells in the murine
CNS, and quantified adhesion molecule expression as a read-out of
activation. We treated bEND.3 cells with VCR (100 nM) for 24 h and
using flow cytometry we observed that both ICAM-1 and VCAM-1 ex-
pression was significantly higher (p < 0.05) than under control
conditions (Fig. 1A–D). We also observed that the expression of P-gly-
coprotein in VCR treated cells was significantly higher (p < 0.05) than
in unstimulated cells (Fig. 1E–F). Furthermore, VCR treatment sig-
nificantly decreased (p < 0.05) trans-endothelial resistance and in-
creased (p < 0.05) paracellular permeability (Fig. 1G, H) suggesting
that VCR treatment alters endothelial functionality.
These data indicate that VCR induces CNS endothelial cell activa-
tion, as we previously observed in the context of the periphery using
primary HUVECs (Old et al., 2014). In addition, the observation that
VCR reduces endothelial resistance and increases permeability of the
endothelium in vitro, suggests that VCR treatment in vivo could result in
alteration of vascular permeability and blood cell trafficking in CNS
tissue.
3.2. Evidence of monocyte trafficking in the spinal cord after VCR systemic
treatment
In order to assess whether VCR-induced changes in the en-
dothelium, and thus potential changes in vascular permeability, were
associated with blood cell trafficking through the endothelium, we
observed monocyte trafficking in mice in which the chemokine receptor
Fig. 4. One cycle of VCR treatment disrupts expression of tight junction proteins in the spinal cord. (A and C) Representative blots of either Claudin-5 (A, 24 kDa) or
ZO-1 (B, 187 kDa) and β -actin loading control (42 kDa) in lumbar spinal cord dorsal horn homogenates obtained from wild-type mice treated with one cycle of VCR
or saline controls (days 0–4 inclusive). (B and D) Quantification of claudin-5 (B) and ZO-1 (D) band density normalised to loading control. VCR treatment sig-
nificantly decreases the expression of both proteins in spinal cord homogenates. (n=3 mice). *p < 0.05, **p < 0.01, one-way ANOVA, post-hoc Tukey test. (E)
Representative images of claudin 5 (green) and CCR2 (RFP, red) in lumbar spinal cord sections (dorsal horn) from saline-treated and VCR-treated mice. Nuclear stain
DAPI in blue. (F) Representative images of ZO-1 (green) and CCR2 (RFP, red) in lumbar spinal cord sections (dorsal horn) from saline-treated and VCR-treated mice.
Nuclear stain DAPI in blue Scale bars in panels in E and F=10 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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CCR2 is RFP-tagged and thus CCR2+ monocytes are labelled with RFP.
CCR2 is not expressed by microglia (Mizutani et al., 2012), and there-
fore the presence of mobile, CCR2 positive cells can be taken as evi-
dence for monocyte trafficking from the blood stream to the adjacent
tissue.
CCR2-RFP mice were injected with VCR and in vivo imaging was
performed in the spinal cord 24 h later. We have previously observed
that mechanical hypersensitivity occurs within 24 h of the first dose of
VCR and that in vitro, the endothelium is activated 24 h after VCR
treatment in vitro and so we attempted to investigate if monocyte in-
filtration into the spinal cord as a result of alterations in the en-
dothelium could play a role in hypersensitivity at this timepoint. In
order to visualise blood vessels and hence distinguish between mono-
cytes that were present in blood and those that were present in tissue,
we injected dextran fluorescein intravenously prior to imaging. We
found that 24 h after a single administration of VCR, a significantly
higher number of RFP+ cells could be observed outside of the blood
vessels i.e. in spinal cord tissue. Specifically, in VCR-treated mice we
found approximately four times more RFP+ cells in spinal cord tissue
compared to controls (p < 0.05) (Fig. 2A–C). Furthermore, we also
observed preliminary evidence for significantly more (p < 0.05) ad-
hesion of RFP+ monocytes at the vessel wall in VCR-treated mice
(Fig. 2D). Indeed, in VCR-treated mice we observed a 2-fold increase in
the number of monocytes located at the endothelium relative to con-
trols suggesting a link between up-regulation of endothelial adhesion
molecules that we observed in vitro, and significant increase in apparent
cell adhesion.
These data indicate that monocytes are likely to infiltrate the spinal
cord after a single dose of VCR, suggesting that endothelial activation at
the BSCB could have occurred, corroborating the in vitro observations
obtained in endothelial cells.
3.3. Alterations in vascular permeability at the end of one cycle of VCR
systemic treatment
To determine whether changes in vascular permeability in the CNS
occur in vivo, and following a more clinically-relevant dosing regime,
we treated mice with one cycle of VCR (5 days) and subsequently as-
sessed Evans Blue (EB) extravasation. Comparable EB amounts were
observed in paws prior to tissue harvesting (Fig. 3A) and likewise si-
milar levels were found in liver tissue from VCR-treated and control
mice (Fig. 3B) indicating that EB delivery and extraction were. Fol-
lowing VCR treatment, we did however measure a significant increase
in the amount of detectable EB in both brain and spinal cord tissue,
relative to controls (Fig. 3C-D). Specifically, in brain tissue from VCR-
treated mice, the amount of EB that could be measured per mg of tissue
Fig. 5. One cycle of VCR treatment results in monocytes/macrophages infiltration and CatS elevation in the spinal cord. (A) Representative images showing
microglia/macrophage marker Iba1 (green) in saline-treated and VCR-treated lumbar spinal cord dorsal horn from CCR2-RFP heterozygous mice. CCR2 im-
munoreactivity (RFP, red, merge yellow) is only found in Iba1+ cells in spinal cords from VCR-treated mice. (B) Representative image showing TMEM119 im-
munoreactivity (green, resident microglia marker). No CCR2 (RFP, red) immunoreactivity is found in TMEM119+ cells. Nuclear marker DAPI in blue. (C)
Representative image showing Ly6C immunoreactivity (green, monocyte/macrophage marker). CCR2 (RFP, red) immunoreactivity is found in Ly6C+ cells. Nuclear
marker DAPI in blue. (D) Representative blot and quantification of CatS (37 kDa) and β -actin loading control (42 kDa) in lumbar spinal cord dorsal horn homo-
genates obtained from wild-type mice treated with one cycle of VCR (or saline controls). One cycle of VCR significantly increases CatS expression. (n=3 mice).
*p < 0.05, one-way ANOVA, Tukey test. (E,F) Representative image showing CatS immunoreactivity (green) in lumbar spinal cord dorsal horn from mice treated
with one cycle of VCR. CCR2 (RFP, red) immunoreactivity is only found in CatS+ cells (yellow) with a phagocytic phenotype. Nuclear marker DAPI in blue. Scale bar
in all panels= 10 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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was more than three times higher (p < 0.01) than that measured in
brain tissue from control mice that had been treated with saline for
5 days (Fig. 3C). Likewise, when we measured EB in spinal cord tissue,
levels were almost four times greater (p < 0.005) in VCR-treated mice
than in tissue from controls (Fig. 3D). These data suggest that CNS
vascular permeability is selectively increased during VCR treatment.
3.4. Disruption of tight junction protein expression and presence of
infiltrating monocytes in the spinal cord after VCR treatment
We then further assessed the integrity of the BSCB after a cycle of
VCR treatment by evaluating tight junction protein expression in order
to assess whether their disruption could account for the increased EB
Fig. 6. CatS inhibitors reduce VCR-induced
mechanical hypersensitivity only when
centrally-penetrant. (A) Mechanical thresh-
olds are significantly higher in VCR-treated
male and female mice (days 0–4 inclusive),
which also received the centrally-penetrant
MIV-247 (MIV) (200 µmol/kg p.o. twice a
day, every day) alongside VCR than in VCR/
vehicle-treated mice. Data expressed as 50%
paw withdrawal thresholds (mean ± SEM,
n=7 mice per group, 4 female and 3 male)
measured 3 h after administration.
***p < 0.001 compared to Saline/VEH
group; ###p < 0.001 compared to VCR/
VEH group, Repeated Measures ANOVA,
post hoc Tukey test. (B) Mechanical thresh-
olds in mice treated with VCR (days 0–4
inclusive) are not altered 3 h after adminis-
tration of the peripherally-restricted
RO5461111 (RO5) (200 µmol/kg p.o. twice
a day, every day) alongside VCR. Data ex-
pressed as 50% paw withdrawal thresholds
(mean ± SEM, n=7 mice per group).
***p < 0.001 compared to Saline/VEH and
Saline/RO5 groups Repeated Measures
ANOVA, post hoc Tukey test. (C-D)
Representative blot (C) and quantification
(D) of li p10 fragment expression relative to
li in snap frozen spleen from R05-treated
and control mice (3 h after administration)
(n= 3 mice ± SEM) **p < 0.01, Student’s
t-test.
K. Montague-Cardoso, et al. Brain, Behavior, and Immunity 83 (2020) 248–259
255
Fig. 7. Changes in vascular permeability following VCR treatment result in the infiltration of monocytes, which play a role in central mechanisms of pain. 1)
Following treatment with vincristine (VCR), endothelial cells at the blood-spinal cord barrier upregulate adhesion molecules and are thus activated. 2a) VCR
treatment also disrupts tight junction organization between endothelial cells and so monocytes, (which express CCR2 and are thus attracted by endothelial-expressed
CCL2), are able to infiltrate into the spinal cord (2b). 3) Infiltrating monocytes provide a source of cathepsin S (CatS). 4) Cat S cleaves fractalkine (FKN) expressed by
dorsal horn neurons. 5) Soluble FKN (sFKN) activates CX3CR1 receptors expressed by microglia, which in turn release proinflammatory, pronociceptive cytokines (6).
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permeability observed at this time point. We used Western blot analysis
and immunohistochemistry in order to assess the expression of claudin-
5 and ZO-1, and their assembly on the endothelium in the murine spinal
cord. We observed that at the end of one cycle of VCR treatment, both
claudin-5 and ZO-1 expression were significantly decreased (p < 0.01
and 0.05, respectively) relative to the expression levels observed in
spinal cord tissue from saline-treated control mice (Fig. 4A–D). In ad-
dition, immunohistochemistry indicated that claudin-5 and ZO-1 or-
ganization was fragmented and that CCR2/RFP+ profiles were clus-
tered in regions where tight junction integrity was suggested to be
disrupted (Fig. 4E–F).
We then investigated whether altered vascular permeability and
potential changes in tight junctions resulted in infiltration of monocytes
into the spinal cord following one cycle of VCR treatment, which was
suggested to occur from as soon as 24 h after the first treatment as
demonstrated by our intravital data.
We detected the presence of RFP(CCR2)+/Iba1+ cells in the lumbar
dorsal horn from VCR-treated mice (Fig. 5A). In the spinal cord Iba1
immunoreactivity is present on both resident microglia and infiltrated
monocytes/macrophages. However, microglia do not express CCR2
(Mizutani et al., 2012) and thus it is possible that RFP+/Iba1+ cells
that are observed in the spinal cord are infiltrated monocytes/ macro-
phages. Indeed, we could not detect RFP signal in cells that were po-
sitive for TMEM119, a specific marker for resident microglia (Fig. 5B).
RFP signal however was detectable within TMEM119-stained sections,
thus the lack of RFP signal in TMEM119 cells was not due to a complete
lack of detectable RFP signal (Suppl. Fig. 1). Furthermore, we were also
able to observe the presence of RFP+ cells that were also positive for
the monocyte/macrophage precursor marker Ly6C in the dorsal horn of
lumbar spinal cord from VCR-treated mice but not from saline-treated
mice after one VCR treatment cycle (Fig. 5C and Suppl. Fig. 2B). Our
immunohistochemical data therefore indicate that monocytes infiltrate
into the spinal cord in the first VCR treatment cycle.
3.5. Functional role for infiltrating monocytes following VCR systemic
treatment
As we are interested in a functional role for infiltrating monocytes in
the development of VCR-induced nociception, we postulated that these
cells would provide a source of the pro-nociceptive enzyme CatS in the
spinal cord. Indeed, monocytes/macrophages-derived CatS exerts a pro-
nociceptive action in the periphery in models of neuropathic pain
(Barclay et al., 2007; Zhao et al., 2014).
Following one cycle of VCR treatment we observed that the ex-
pression of CatS in the lumbar spinal cord significantly increased
(p < 0.05), as demonstrated by Western blot analysis (Fig. 5D). Fur-
thermore, not only did we observe CatS immunoreactivity in Iba1+
cells, which is expected since CatS is normally expressed by microglia
(Fig. 5E), we also detected CatS immunoreactivity in RFP+ cells that
possessed a morphology associated with phagocytic cells such as mac-
rophages (Fig. 5F).
Taken together, these data suggest that monocytes expressing CatS
infiltrate into the spinal cord following VCR treatment and provide an
additional source of the enzyme alongside the microglia. It is plausible
that monocytes/macrophages release CatS instead of microglia, which
are not activated following VCR treatment (Old et al., 2014). In order to
validate the biological significance of infiltrating monocyte-derived
CatS, we investigated whether administration of a CatS inhibitor af-
fected the development of allodynia.
3.6. A centrally-penetrant Cathepsin s inhibitor is effective in reducing VCR-
induced nociception
In light of the data presented so far, we postulated that monocytes
infiltrate into the spinal cord during VCR treatment and once there,
could contribute to allodynia via the release of CatS that liberates
neuronal fractalkine, thus activating CX3CR1 receptors that are con-
stitutively expressed by microglia (Clark et al., 2007).
The administration of a centrally-penetrant CatS inhibitor (MIV-
247) (Hewitt et al., 2016) significantly (p < 0.001) reduced VCR-in-
duced mechanical hypersensitivity within 24 h of the first dose being
administered and this effect persisted throughout the first VCR treat-
ment cycle (Fig. 6A). However, equimolar administration of a periph-
erally-restricted CatS inhibitor (RO5461111) to VCR-treated mice
during the first treatment cycle did not delay the onset or reduce the
severity of VCR-induced mechanical hypersensitivity. Indeed, there was
no difference in the paw withdrawal thresholds between VCR-treated
mice who had received RO5461111 and those that had received the
vehicle (Fig. 6B). To ensure that this lack of effect of RO5461111 was
due to the antagonist's peripheral restriction and not to an insufficient
dose or poor oral bioavailability, we tested CatS target engagement for
the antagonist in spleen tissue as a positive control. In the presence of a
CatS inhibitor, the cleavage of Lip P10 (P10) in B-lymphocytes and
dendritic cells is blocked, resulting in accumulation of P10. Indeed, in
spleen homogenates isolated from RO5461111-treated mice, we ob-
serve significant P10 accumulation (p < 0.01) suggesting that the
antagonist is biologically active in the periphery under these experi-
mental conditions (Fig. 6C, D).
The observation that VCR-induced nociception was only sig-
nificantly reduced when a centrally-penetrant CatS antagonist was
used, does suggest that CatS plays a role centrally in mediating VCR
mechanisms.
4. Discussion
Chemotherapy-induced neuropathic pain is a dose-limiting side ef-
fect of many cancer therapies that has the capacity to diminish their
success (Seretny et al., 2014). It is therefore critical that our under-
standing of the underlying mechanisms of chemotherapy pain is ad-
vanced and thus the development of new, more effective therapies for
pain is aided. We elucidated a previously unappreciated pathway by
which changes in vascular permeability in the spinal cord following
VCR treatment result in infiltration of CCR2+ monocytes that con-
tribute to allodynia via the pro-nociceptive enzyme CatS (Fig. 7).
This phenomenon provides a potential means by which commu-
nication between peripheral immune cells and dorsal horn neurons/
sensory neuron terminals in the spinal cord mediates nociceptive hy-
persensitivity during VCR treatment.
We uncover a potential role for monocytes expressing CatS in the
development of VCR-induced allodynia with CatS activity being more
critical in the spinal cord than in the peripheral nerve. Specifically, we
show that VCR-induced allodynia is significantly prevented by admin-
istration of a centrally penetrant, but not by a peripherally-restricted,
CatS inhibitor. We have previously shown that in peripheral nerves
VCR-induced activation of the endothelium results in infiltration of
monocytes/macrophages. In these cells the activation of CX3CR1 re-
ceptors by FKN results in production of ROS, which can activate TRPA1
channels and transmit pain signalling (Old et al., 2014). Although we
know that CatS enzymatically cleaves FKN (Clark et al., 2007, 2009),
solubilisation of endothelial FKN in peripheral nerves does not appear
to contribute to VCR-induced allodynia. Indeed we found that a per-
ipherally-restricted CatS antagonist is devoid of anti-nociceptive effects.
We discounted the possibility that this was due to lack of compound
bioavailability and in vivo activity by confirming P10 accumulation in
spleen. In contrast, the significant anti-nociceptive effect of a centrally-
penetrant CatS inhibitor indicates that CatS derived from a central
source plays a role in VCR-induced allodynia.
In the CNS, CatS is expressed and released by microglia (Clark et al.,
2007, 2010). However, changes in microglial number and morphology
are not apparent in preclinical chemotherapy models (Old et al., 2014)
suggesting that the microglial response is relatively mild and they are
therefore unlikely to release significant amounts of CatS during VCR
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treatment. We suggest that monocytes/macrophages in the spinal cord
provide a source of CatS, which we know can solubilise neuronal FKN
that activates CX3CR1 receptor constitutively expressed by microglia.
Specifically, we delineated a mechanistic pathway that starts with a
systemic VCR-mediated increase in vascular permeability and en-
dothelial activation in the spinal cord, which are followed by the con-
sequential infiltration of monocytes/macrophages. We provide evi-
dence for VCR’s ability to induce up-regulation of endothelial adhesion
molecules, increase CNS vascular permeability and reduce cell re-
sistance. We corroborate these in vitro data with an in vivo series of data
that demonstrate increase of vascular permeability, monocyte traf-
ficking and an increased in CatS expression in the spinal cord after VCR
treatment.
Indeed, we found evidence that permeability of the spinal cord and
brain is elevated at the end of VCR treatment as indicated by EB ex-
travasation. Within 24 h of VCR treatment we found upregulation of
adhesion molecules in endothelial cells in vitro, whilst in vivo we ob-
served a significant increase in monocytes (CCR2+ cells) in spinal cord
tissue as well as a significant increase in cells adhering to the vessel
wall, which is the first step of monocyte infiltration (Gerhardt and Ley,
2015). Due to practical limitations however, the time series that we
obtained were not long enough to observe infiltration, which would
take hours longer than the maximum of 1 h that we were able to obtain.
Furthermore, we found evidence to suggest that tight junction in-
tegrity is disrupted in the spinal cord of VCR-treated mice. Specifically,
we observed a decrease in the expression of the tight junction proteins
claudin-5 and ZO-1 in lumbar dorsal spinal cord as well as a change in
protein organization as suggested by our immunohistochemical data.
Therefore, alterations in permeability of the BSCB at the end of one VCR
treatment cycle could be a result of changes in tight junction protein
expression. Furthermore, our observation the CCR2/RFP+ profiles ac-
cumulated in regions where tight junction protein organization ap-
peared to be disrupted suggests that infiltration of monocytes/macro-
phages could be aided by the disruption of endothelial tight junctions in
the spinal cord.
Indeed, we observed the presence of Iba1-positive cells that were
also positive for CCR2/RFP in the lumbar spinal cord. Both microglia
and monocytes/macrophages express Iba1 and yet microglia do not
express CCR2 (Mizutani et al., 2012) and we observed no RFP signal in
cells that were positive for the microglial marker TMEM119. This
suggests that the origin of Iba1+/RFP+ cells in the spinal cord fol-
lowing VCR treatment is not microglia and indeed we observe cells that
are positive for the monocyte/macrophage precursor marker; Ly6C in
the spinal cord following one cycle of VCR treatment that are also po-
sitive for CCR2/RFP. It is also very likely that infiltrating monocytes/
macrophages provide a source of CatS, as we also observe an increase in
CatS protein expression after one cycle of VCR.
Finally, it is worth noting that endothelial cells in the CNS do not
express FKN (Kim et al., 2011), therefore soluble FKN is unlikely to be
the mechanism that accounts for CX3CR1-expressing monocyte traf-
ficking in this case.
Overall our study highlights the significance of the interaction be-
tween peripheral immune cells and nociceptive neurons in the spinal
cord, which mediates nociceptive hypersensitivity during VCR treat-
ment, a potential prototype for other chemotherapy drugs. Obtaining a
better understanding of alterations in vascular permeability that occur
as a result of VCR treatment begins to guide us towards a better un-
derstanding of potential central mechanisms that regulate pain asso-
ciated this pain.
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